Published in Clin Cancer Res on August 01, 2006
Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res (2011) 1.59
The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology (2009) 1.30
Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol (2007) 1.28
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Selection of optimal reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics (2010) 1.11
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C. Toxins (Basel) (2010) 0.94
Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys (2014) 0.93
Molecular staging individualizing cancer management. J Surg Oncol (2012) 0.90
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. Cancer Res (2009) 0.90
Colorectal cancer immunotherapy. Discov Med (2013) 0.87
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol (2009) 0.87
Molecular staging of node negative patients with colorectal cancer. J Cancer (2013) 0.86
Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res (2013) 0.86
The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.86
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget (2014) 0.85
GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome? Drug News Perspect (2009) 0.85
Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J Surg Oncol (2012) 0.83
Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin Transl Sci (2008) 0.83
Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer (2013) 0.82
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. Hum Pathol (2009) 0.82
Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer (2011) 0.81
Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis (2008) 0.81
GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev Mol Diagn (2009) 0.80
Guanylyl cyclase C as a biomarker in colorectal cancer. Biomark Med (2013) 0.79
Current status of gene expression profiling to assist decision making in stage II colon cancer. Oncologist (2014) 0.79
Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel) (2010) 0.79
Can colorectal cancer be prevented or treated by oral hormone replacement therapy? Curr Mol Pharmacol (2009) 0.79
STa peptide analogs for probing guanylyl cyclase C. Biopolymers (2008) 0.78
GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med (2012) 0.78
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Rev Clin Pharmacol (2013) 0.78
Previstage GCC test for staging patients with colorectal cancer. Expert Rev Mol Diagn (2008) 0.78
A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. BMC Cancer (2016) 0.78
Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8(+) T Cells. J Immunol (2017) 0.78
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology (2016) 0.77
Sex modulates intestinal transformation by the tumor-suppressor GCC. Clin Transl Sci (2008) 0.75
Sex modulates intestinal transformation by the tumor-suppressor GCC. Clin Transl Sci (2008) 0.75
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother (2002) 2.68
A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer (2007) 2.64
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A (2007) 1.90
Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene (2005) 1.90
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Tailored navigation in colorectal cancer screening. Med Care (2008) 1.79
Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med (2004) 1.68
Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle (2012) 1.63
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology (2007) 1.63
G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension (2009) 1.62
Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res (2011) 1.59
First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol (2003) 1.55
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol (2014) 1.49
Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med (2009) 1.41
Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol (2005) 1.32
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res (2005) 1.31
Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg (2009) 1.29
A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood (2011) 1.28
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol (2007) 1.28
A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest (2011) 1.27
Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet (2003) 1.27
Risk of second cancers in patients with colorectal carcinoids. Dis Colon Rectum (2002) 1.26
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res (2005) 1.26
High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat (2008) 1.22
Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med (2003) 1.21
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA (2007) 1.20
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2011) 1.18
Racial differences in severe perineal lacerations after vaginal delivery. Am J Obstet Gynecol (2003) 1.17
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res (2002) 1.17
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J (2008) 1.15
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol (2003) 1.15
Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J (2006) 1.13
GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One (2012) 1.13
GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer (2011) 1.13
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.12
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol (2011) 1.12
Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol (2010) 1.11
Selection of optimal reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics (2010) 1.11
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer (2010) 1.10
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol (2006) 1.09
Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology (2006) 1.09
Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. J Med Chem (2002) 1.09
Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg (2008) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck (2009) 1.07
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn (2005) 1.07
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol (2010) 1.06
Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther (2011) 1.05
Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol (2004) 1.05
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res (2010) 1.04
Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer (2013) 1.03
Colorectal cancer screening. J Natl Compr Canc Netw (2013) 1.02
Relative quantification based on logistic models for individual polymerase chain reactions. Stat Med (2007) 1.02
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation (2013) 1.01
A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes? J Gastrointest Surg (2012) 1.00
Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res (2004) 1.00
Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation (2011) 1.00
Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. J Pediatr Surg (2004) 0.99
Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol (2013) 0.98
Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res (2014) 0.97
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand. J Nucl Med (2002) 0.97
Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res (2005) 0.96
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol (2007) 0.96
Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomark Med (2007) 0.95
Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle (2013) 0.95